Literature DB >> 10533066

Mutation screening of the entire coding regions of the TSC1 and the TSC2 gene with the protein truncation test (PTT) identifies frequent splicing defects.

K Mayer1, W Ballhausen, H D Rott.   

Abstract

Mutation analyses in tuberous sclerosis (TSC) have reported a wide variety of disease-causing aberrations in the two known predisposing genes, TSC1 and TSC2 on chromosomes 9q34 and 16p13, comprising mainly small mutations distributed over the entire genes. So far, all known TSC1 mutations as well as the majority of TSC2 mutations truncate the proteins hamartin and tuberin, respectively. We describe for the first time an RNA-based screening of the entire coding regions of both TSC genes for truncating mutations applying the protein truncation test (PTT). Simultaneous investigation of both TSC genes in a group of 48 unassigned TSC patients, which were previously tested to exclude large intragenic TSC2 rearrangements, revealed aberrant migrating polypeptides resulting from truncating mutations in nine TSC1 cases and in 16 TSC2 cases while three TSC2 cases showed enlarged proteins. TSC1 mutations include two nonsense mutations, four insertions, and three splice mutations. Nineteen mutations identified in TSC2 were composed of four different nonsense mutations in five patients, one deletion, one insertion, and seven different splicing aberrations due to at least eight different mutations found in 12 patients. Additional predicted truncating mutations according to PTT without possible identification of the causative alteration allowed assignment to TSC1 in one and TSC2 in seven cases. Twelve patients without abnormalities in the PTT are assumed to harbor missense mutations, probably in TSC2. The high proportion of TSC2 splicing aberrations strengthens the importance of intronic disease-causing mutations and the application of RNA-based screening methods to confirm their consequences. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10533066     DOI: 10.1002/(SICI)1098-1004(199911)14:5<401::AID-HUMU6>3.0.CO;2-R

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  9 in total

1.  Characterisation of TSC1 promoter deletions in tuberous sclerosis complex patients.

Authors:  Ans M W van den Ouweland; Peter Elfferich; Bernard A Zonnenberg; Willem F Arts; Tjitske Kleefstra; Mark D Nellist; Jose M Millan; Caroline Withagen-Hermans; Anneke J A Maat-Kievit; Dicky J J Halley
Journal:  Eur J Hum Genet       Date:  2010-09-29       Impact factor: 4.246

2.  Clinical utility gene card for: tuberous sclerosis complex (TSC1, TSC2).

Authors:  Karin Mayer; Christa Fonatsch; Katharina Wimmer; Ans M W van den Ouweland; Anneke J A Maat-Kievit
Journal:  Eur J Hum Genet       Date:  2013-06-12       Impact factor: 4.246

3.  Molecular nature of 11 spontaneous de novo mutations in Drosophila melanogaster.

Authors:  H P Yang; A Y Tanikawa; A S Kondrashov
Journal:  Genetics       Date:  2001-03       Impact factor: 4.562

4.  Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs.

Authors:  S L Dabora; S Jozwiak; D N Franz; P S Roberts; A Nieto; J Chung; Y S Choy; M P Reeve; E Thiele; J C Egelhoff; J Kasprzyk-Obara; D Domanska-Pakiela; D J Kwiatkowski
Journal:  Am J Hum Genet       Date:  2000-12-08       Impact factor: 11.025

5.  Synaptic signaling and aberrant RNA splicing in autism spectrum disorders.

Authors:  Ryan M Smith; Wolfgang Sadee
Journal:  Front Synaptic Neurosci       Date:  2011-01-26

6.  Response to everolimus is seen in TSC-associated SEGAs and angiomyolipomas independent of mutation type and site in TSC1 and TSC2.

Authors:  David J Kwiatkowski; Michael R Palmer; Sergiusz Jozwiak; John Bissler; David Franz; Scott Segal; David Chen; Julian R Sampson
Journal:  Eur J Hum Genet       Date:  2015-03-18       Impact factor: 4.246

7.  Mosaic and Intronic Mutations in TSC1/TSC2 Explain the Majority of TSC Patients with No Mutation Identified by Conventional Testing.

Authors:  Magdalena E Tyburczy; Kira A Dies; Jennifer Glass; Susana Camposano; Yvonne Chekaluk; Aaron R Thorner; Ling Lin; Darcy Krueger; David N Franz; Elizabeth A Thiele; Mustafa Sahin; David J Kwiatkowski
Journal:  PLoS Genet       Date:  2015-11-05       Impact factor: 5.917

8.  Molecular analysis of TSC1 and TSC2 genes and phenotypic correlations in Brazilian families with tuberous sclerosis.

Authors:  Clévia Rosset; Filippo Vairo; Isabel Cristina Bandeira; Rudinei Luis Correia; Fernanda Veiga de Goes; Raquel Tavares Boy da Silva; Larissa Souza Mario Bueno; Mireille Caroline Silva de Miranda Gomes; Henrique de Campos Reis Galvão; João I C F Neri; Maria Isabel Achatz; Cristina Brinckmann Oliveira Netto; Patricia Ashton-Prolla
Journal:  PLoS One       Date:  2017-10-02       Impact factor: 3.240

9.  Novel and de novo mutations in pediatric refractory epilepsy.

Authors:  Jing Liu; Lili Tong; Shuangshuang Song; Yue Niu; Jun Li; Xiu Wu; Jie Zhang; Clement C Zai; Fang Luo; Jian Wu; Haiyin Li; Albert H C Wong; Ruopeng Sun; Fang Liu; Baomin Li
Journal:  Mol Brain       Date:  2018-09-05       Impact factor: 4.041

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.